Annals of Oncology
Annals of Oncology is ESMO's flagship journal, publishing European phase 3 trials, the ESMO Clinical Practice Guidelines and the abstract books for the ESMO Congress.
Annals of Oncology appears monthly and publishes the ESMO Clinical Practice Guidelines (free to read), ESMO-MCBS benefit scores, trial results often presented at ESMO Congress, translational biomarker studies and the ESMO congress abstract supplements. Published by Elsevier since 2019 (previously Oxford University Press). Hybrid access.
GI oncologist who led CALGB/SWOG 80405 and helped show that tumour side matters in colorectal cancer.
Breast trialist who co-led OlympiA, showing adjuvant olaparib improves survival in BRCA carriers.
Prostate cancer trialist who helped bring abiraterone and sipuleucel-T to patients, and led ASCO in 2025-26.
Breast oncologist who led MONARCH 3 and studies how genetics shapes response to endocrine therapy.
Created the ESMO Magnitude of Clinical Benefit Scale, the standard tool for grading how much a cancer drug really helps.
Leads the German Breast Group, whose GeparX trials defined neoadjuvant chemotherapy and immunotherapy in breast cancer.
Pages like this
not linked directly; found by shared links- IdeaA guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer
Shares ESMO Clinical Practice Guidelines & MCBS, European Society for Medical Oncology (ESMO).
- IdeaGuidelines list the open trials at every decision point, updated monthly
Shares ESMO Clinical Practice Guidelines & MCBS, European Society for Medical Oncology (ESMO).
- IdeaLiving guidelines published as versioned, computable rules
Shares ESMO Clinical Practice Guidelines & MCBS, European Society for Medical Oncology (ESMO).